Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNeumora Therapeutics, Inc.

Neumora Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.4692 USD -0.00 ( 0.80%)
Last update at 2026-11-12T15:50:00Z
VOLUME
425944
Market Cap
156.20M

Momentum Score

…

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.44
Low
0.49
High
52 Week Price Range
0.83
Low
3.65
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.47
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-187.11%
Net Debt
-182.05M
ROCE
-147.28%
Diluted EPS TTM
-1.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -236.80M -243.61M -235.66M -130.90M -237.31M
Net income -236.93M -243.79M -235.93M -130.90M -237.31M
Selling general administrative 60.09M 62.54M 45.48M 31.12M 24.55M
Selling and marketing expenses - - 0.67M - -
Gross profit -5.00M - -0.67M - -
Reconciled depreciation 0.21M 0.63M 0.67M 0.59M 0.54M
Ebit -233.58M -243.61M -235.66M -135.87M -237.32M
Ebitda -233.37M -242.98M -234.99M -135.28M -236.78M
Depreciation and amortization 0.21M 0.63M 0.67M 0.59M 0.54M
Operating income -241.16M -263.46M -188.19M -135.87M -237.32M
Other operating expenses 241.16M 263.46M 188.19M 135.87M 237.32M
Interest expense 3.22M - - - -
Tax provision 0.13M 0.18M 0.27M - -
Interest income 8.34M 19.93M 16.61M 4.56M -
Net interest income 5.12M 19.93M 16.61M 4.56M -
Income tax expense 0.13M 0.18M 0.27M -4.56M -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 236.16M 263.46M 187.53M 135.87M 237.32M
Cost of revenue 5.00M - 0.67M - -
Total other income expense net 4.36M 19.86M -47.46M 0.41M 0.01M
Net income from continuing ops -236.93M -243.79M -235.93M -130.90M -237.31M
Net income applicable to common shares - - - -130.90M -237.31M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 191.05M 316.97M 496.19M 426.23M 429.30M
Other current assets 8.01M 6.48M - 13.53M 4.96M
Total liab 87.18M 29.91M 27.12M 873.08M 754.52M
Total stockholder equity 103.87M 287.06M 469.08M -446.85M -325.22M
Deferred long term liab - - - 2.91M 1.83M
Other current liab 28.79M 24.73M 0.14M 13.18M 20.58M
Common stock 0.02M 0.02M 0.02M 0.02M 0.01M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.01M
Retained earnings -1184.15M -947.22M -703.43M -467.51M -336.61M
Other liab - - - 0.63M 0.39M
Other assets - - - 4.13M 9.65M
Cash 182.53M 142.15M 374.04M 240.94M 409.25M
Total current liabilities 32.45M 29.89M 25.11M 23.70M 23.28M
Current deferred revenue - - 21.26M 11.54M 19.10M
Net debt -182.05M -140.29M -368.81M -232.50M -407.19M
Short term debt 0.28M 1.85M 3.38M 3.37M 1.06M
Short long term debt total 0.48M 1.85M 5.23M 8.44M 2.05M
Other stockholder equity 1288.00M 1234.21M 1172.57M 21.42M 11.37M
Property plant equipment - - - 10.64M 4.04M
Total current assets 190.54M 314.06M 478.28M 387.95M 415.60M
Long term investments - 0.00M 9.85M 23.51M -
Net tangible assets - - - -446.85M -325.22M
Short term investments 0.00M 165.43M 79.94M 130.94M -
Net receivables - - 0.94M 0.92M 0.20M
Long term debt 54.53M - - - -
Accounts payable 3.38M 3.31M 0.34M 7.15M 1.64M
Accumulated other comprehensive income - 0.06M -0.08M -0.77M -
Non currrent assets other 0.05M - 1.21M 4.13M 9.65M
Non current assets total 0.51M 2.92M 17.92M 38.28M 13.69M
Capital lease obligations 0.48M 1.85M 5.23M 8.44M 2.05M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 168.30M -70.56M 64.39M -168.01M -0.82M
Change to liabilities - - - -1.25M -0.76M
Total cashflows from investing activities 168.52M -70.56M 64.39M -168.01M -0.82M
Net borrowings 57.16M 0.00M - - -
Total cash from financing activities 77.09M 21.60M 231.94M 115.74M 293.51M
Change to operating activities - - - -5.70M -0.20M
Net income -236.93M -243.79M -235.93M -130.90M -237.31M
Change in cash 39.17M -231.89M 133.04M -167.17M 217.27M
Begin period cash flow 143.36M 375.25M 242.21M 409.37M 192.10M
End period cash flow 182.53M 143.36M 375.25M 242.21M 409.37M
Total cash from operating activities -206.44M -182.94M -163.28M -114.90M -75.42M
Issuance of capital stock 19.65M 13.69M 233.38M 112.22M 292.14M
Depreciation 0.21M 0.63M 0.67M 0.59M 0.54M
Other cashflows from investing activities 3.15M -0.78M -4.59M - -
Sale purchase of stock - 0.00M -0.49M - 0.00M
Other cashflows from financing activities 77.09M 7.91M -0.95M 115.74M 292.55M
Change to netincome - - - 22.36M 162.31M
Capital expenditures 0.00M 0.00M 0.12M 0.51M 0.82M
Change in working capital -0.44M 22.64M -8.90M -6.95M -0.96M
Stock based compensation 29.88M 39.99M 17.24M 8.30M 4.27M
Other non cash items 0.84M -1.77M 63.64M 14.06M 158.04M
Free cash flow -206.44M -182.94M -163.40M -115.41M -76.24M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NMRA
Neumora Therapeutics, Inc.		 -0.00
0.80%		 0.47 - - - 4.18 -4.65
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

260 Arsenal Place, Watertown, MA, United States, 02472

857 760 0900

https://www.neumoratx.com

63

Name Title Year Born
Mr. Paul L. Berns Co-Founder & Executive Chairman 1967
Mr. Joshua Pinto Ph.D. CFO & Treasurer 1985
Mr. Henry O. Gosebruch President, CEO & Director 1973
Ms. Carol Suh Co-Founder & COO 1989
Dr. Robert Michael Poole FACP, M.D. Co-Founder & Advisor 1958
Mr. Michael Lee Milligan Principal Accounting Officer NA
Dr. Rajesh Manchanda Ph.D. Chief Technical Operations Officer 1966
Mr. Nicholas Brandon Ph.D. Chief Scientific Officer 1974
Mr. Jason G. Duncan Chief Legal Officer 1974
Amy Sullivan Senior Vice President of Human Resources NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…